Stock AnalizGilead Sciences, Inc. GILD
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 1992 · data as of November 13, 2026
Gilead Sciences, Inc. (GILD) is a healthcare company listed in the US with a market value of about $208.5B. In the twelve months to September 30, 2026 it had revenue of $31.0B and net income of -$3.9B, a net margin of -12.5%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is track record (4/5); the weakest is value (1/5).
Key numbers: a price to free cash flow of 15.1, 5-year revenue growth of 4% a year, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 35% below the current price.
Score: 2.8 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.0B | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B | $24.7B | $22.4B | $22.1B | $26.1B | $30.4B |
| Net income | -$3.9B | $8.5B | $480M | $5.7B | $4.6B | $6.2B | $123M | $5.4B | $5.5B | $4.6B | $13.5B |
| Free cash flow | $13.8B | $9.5B | $10.3B | $7.4B | $8.3B | $10.8B | $7.5B | $8.3B | $7.5B | $11.3B | $16.3B |
| EPS (diluted) | $-3.16 | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 |
| Net margin | -12.5% | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.6% | 17.7% | 44.4% |
| ROIC | — | 18.1% | 2.5% | 12.8% | 12.2% | 15.4% | 6.4% | 7.1% | 11.7% | 20.7% | 30.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 26 analysts is $174.77, 4% above the current price; targets range from $131.00 to $200.00; the consensus rating is “Buy”; expected EPS is $-0.98 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Gilead Sciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 35% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Gilead Sciences pay a dividend?
Yes. The dividend yield is about 1.93%, and it has paid dividends for 10 years in our data.
Is Gilead Sciences a good stock to buy?
We do not give buy or sell advice. Gilead Sciences scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.